Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
AssigneeSequoia Sciences, Inc.
InventorsGary Eldridge, Steven M Martin
Life of this patent
Estimating the term…
Abstract
This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.
Claims30
A method for administering a vaccine composition to a human comprising the steps of:
- administering to the human a vaccine composition comprising an adjuvant formulation comprising about 20 μg to about 50 μg of phosphorylated hexaacyl disaccharide, a phosphatidylcholine, and a buffer selected from the group consisting of citrate and succinate from about 10 mM to about 50 mM, wherein the phosphatidylcholine is at a molar ratio with phosphorylated hexaacyl disaccharide at about 1:1 to about 20:1, and the vaccine composition is an aqueous buffered suspension.
A method for administering a vaccine composition to a human comprising the steps of:
- administering to the human a vaccine composition comprising an adjuvant formulation comprising about 20 μg to about 50 μg of phosphorylated hexaacyl disaccharide;
- phosphatidylcholine at a molar ratio with phosphorylated hexaacyl disaccharide at about 2:1 to about 5:1;
- phosphatidylcholine is selected from the group consisting of DMPC, DPPC, DSPC, POPC, and DOPC;
- and a buffer selected from the group consisting of citrate and succinate from 15 mM to about 50 mM, wherein the vaccine composition is an aqueous buffered suspension.
An adjuvant formulation for a vaccine comprising:
- phosphorylated hexaacyl disaccharide;
- a phosphatidylcholine;
- and,
- a buffer selected from the group consisting of citrate and succinate,
- wherein the buffer concentration is from about 10 mM to about 50 mM, and the phosphatidylcholine is at a molar ratio with phosphorylated hexaacyl disaccharide at about 1:1 to about 20:1.
Dependencies are inferred from the claim text.